the present invention is defined with further reference to the following examples , which describe the preparation and usage of the crystal forms in the present invention in details . it is obvious to the technicians in this field that various changes in materials and methods may be embodied without deviating from the scope of the present invention . the instrument for x - ray powder diffraction ( xprd ) is bruker d8 advance diffractometer , which equips θ - 2θ goniometer , mo monochromator and lynxeye detector . the acquisition software is diffrac plus xprd commander . prior to use , the instrument is calibrated with the standard substance ( generally corindon ) attached . the testing conditions are : range of scanning angle 2θ : 3 ˜ 40 °; step size : 0 . 02 °; speed : 0 . 2 s / step . the testing processes are : use the cu kα x - ray with 1 . 54 nm in wavelength , under the operation conditions of 40 kv and 40 ma , the sample is examined at room temperature , and place the test sample on sample holder . unless otherwise specified , samples are not ground before examining . the differential scanning calorimeter ( dsc ) data are collected by ta instruments q200 mdsc ; the instrument control software is thermal advantage and the analysis software is universal analysis . generally , take 1 ˜ 10 mg of the sample and place it in an uncovered ( unless otherwise specified ) aluminum pan and under the protection of 50 ml / min dry n 2 , heat the sample from room temperature to 275 ° c . at the heating rate of 10 ° c ./ min ; and heat changes of the sample during the course are recorded by ta software simultaneously . in the present application , the melting point is reported based on dsc onset temperature . the thermogravimetric analysis ( tga ) data are collected by ta instruments q500 tga ; the instrument control software is thermal advantage and the analysis software is universal analysis . generally , take 5 ˜ 15 mg sample and place it in a platinum pan , adopt the segmental high - resolution testing mode , and under the protection of 50 ml / min dry n 2 , heat the sample from room temperature to 350 ° c . at the heating rate of 10 ° c ./ min , the weight changes of the sample during the course are recorded by ta software simultaneously . the dynamic vapor sorption analysis ( dvs ) data are collected by ta instruments q5000 tga ; the instrument control software is thermal advantage and the analysis software is universal analysis . generally , take 1 ˜ 10 mg of the sample and place it in a platinum pan , and the weight changes of the sample are recorded during the course of the relative humidity changing from 0 % to 80 % and then to 0 %. according to the specifics of the samples , different adsorption and desorption steps may be used . the proton nuclear magnetic resonance spectroscopy ( 1 hnmr ) data are collected by bruker avance ii dmx 400m hz nmr spectrometer . weigh 1 - 5 mg of the sample , dissolve it with 0 . 5 ml dmso - d6 to get a 2 mg / ml - 10 mg / ml solution . the analysis data of high performance liquid chromatography ( hplc ) are collected by agilent 1260 with the chemical working station of b . 04 . the corresponding hplc parameters in this research are : chromatographic column sb - c18 250 × 4 . 6 mm 5 μm ; column temperature 35 ° c . ; flow rate 0 . 6 ml / min ; flow phase as shown below ; wavelength 254 nm ; sample inject volume 20 μl ; operation time 30 min . unless otherwise specified , all the examples are operated at room temperature , the range of temperature is 10 ° c .˜ 30 ° c . the ultrasonic operation is : keep the ultrasonic treatment for 5 minutes at the power of 40 khz . refer to the preparation method described in example 58a and 58d of patent documents wo2009 / 137391 or cn200980126781 . 6 , with the details as follows : add n -{ 3 -[ 5 -( 2 - chloro - 4 - pyrimidinyl )- 2 -( 1 , 1 - dimethylethyl )- 1 , 3 - thiazol - 4 - yl ]- 2 - fluorophenyl }- 2 , 6 - difluorobenzenesulfonamide ( 196 mg , 0 . 364 mmol ) and 7m methanol solution of ammonia ( 8 ml 56 mmol ) into a 25 ml autoclave , heat to 90 ° c . and react for 24 h ; when the tlc shows complete reaction of the raw material , cool the above reaction system to room temperature , concentrate the solvent to dryness , then treat the residues by the column chromatography to get 90 mg n -{ 3 -[ 5 -( 2 - amino - 4 - pyrimidinyl )- 2 -( 1 , 1 - dimethylethyl )- 1 , 3 - thiazol - 4 - yl ]- 2 - fluorophenyl }- 2 , 6 - difluorobenzenesulfonamide , yield : 45 %. add methylsulfonic acid ( 0 . 131 ml , 0 . 393 mmol ) into the isopropanol solution of n -{ 3 -[ 5 -( 2 - amino - 4 - pyrimidinyl )- 2 -( 1 , 1 - dimethylethyl )- 1 , 3 - thiazol - 4 - yl ]- 2 - fluorophenyl }- 2 , 6 - difluorobenzenesulfonamide ( 204 mg , 0 . 393 mmol ) and stir the solution at room temperature for 3 h to obtain a white precipitate , filter the slurry and wash it with ethyl ether to obtain n -[ 3 -[ 5 -( 2 - amino - 4 - pyrimidinyl )- 2 -( 1 , 1 - dimethylethyl )- 1 , 3 - thiazo - 4 - yl ]- 2 - fluorophenyl ]- 2 , 6 - difluorobenzenesulfonamide methanesulfonate , which is a white crystals ( 221 mg , 87 % yield ). 1 hnmr ( 400 mhz , dmso - d6 ) δ ppm 10 . 85 ( s , 1h ) 7 . 92 - 8 . 05 ( m , 1h ), 7 . 56 - 7 . 72 ( m , 1h ), 6 . 91 - 7 . 50 ( m , 7h ), 5 . 83 - 5 . 98 ( m , 1h ), 2 . 18 - 2 . 32 ( m , 3h ), 1 . 36 ( s , 9h ). the x - ray powder diffraction pattern of the obtained crystals as shown in fig1 is consistent with that mentioned in the patent documents wo2009 / 137391 or cn200980126781 . 6 . the dsc thermogram is shown in fig1 : the melting range of the known crystal form i is 247 ° c .˜ 250 ° c . the tga thermogram is shown in fig1 : the decomposition temperature is 261 ° c . place 10 . 02 mg of crystal form iv ( prepared via example 7 ) in a 5 ml vial , add 0 . 5 ml water , sonicate it to get a suspension , stir it for 15 minutes at room temperature , centrifuge the suspension , and then separate the solids without drying to get crystal form ii described by the present invention . the product is 10 . 00 mg and the yield is 99 %. the x - ray powder diffraction pattern is shown in fig6 . the tga thermogram is shown in fig7 : the weight loss of crystal form ii prior to 50 ° c . is about 4 . 6 % ( approximately 1 . 5 water molecules ), the weight loss of crystal form ii from 50 ° c .˜ 155 ° c . is about 1 . 4 % ( approximately 0 . 5 water molecule ), the decomposition temperature is 287 ° c . place 4 . 58 mg of the known crystal form i in a 5 ml vial , add 1 ml methanol and 2 ml butanone ( the amount of the known crystal form i is 0 . 1 times of its solubility in the mixed solvent at room temperature ), sonicate it for 5 min to get a clear solution , then filter it with 0 . 45 μm organic filter membrane , place the filtrate in an uncovered 5 ml vial and evaporate it to recrystallize under nitrogen blowing , after 10 min , centrifuge to separate the solids , without drying , get crystal form iii described by the present invention . the product is 4 . 02 mg and the yield is 88 %. the x - ray powder diffraction pattern is as shown in fig8 . place 5 . 98 mg of the known crystal form i in a 20 ml vial , add 5 ml methanol and 0 . 05 ml ethyl acetate ( the amount of the known crystal form i is 1 time of its solubility in the mixed solvent at room temperature ), sonicate for 5 min to get a clear solution , then filter it with 0 . 45 μm organic filter membrane , place the filtrate in an uncovered 20 ml vial and evaporate to recrystallize under nitrogen blowing at 40 ° c ., after 60 min , separate the solids by centrifugation , without drying , get crystal form iii described by the present invention . the solids are 3 . 22 mg and the yield is 54 %. the x - ray powder diffraction pattern is substantially consistent with that of fig8 . place 5 . 54 mg of the known crystal form i in a 5 ml vial , add 1 . 5 ml methanol and 0 . 3 ml ethyl ether ( the amount of the known crystal form i is 0 . 8 times of its solubility in the mixed solvent at room temperature ), sonicate for 5 min to get a clear solution , then filter it with 0 . 45 μm organic filter membrane , place the filtrate in an uncovered 5 ml vial and evaporate to recrystallize under nitrogen blowing , after 1 min , separate the solids by centrifugation , without drying , get crystal form iii described by the present invention . the resulting solids are 4 . 85 mg and the yield is 87 %. the x - ray powder diffraction pattern is substantially consistent with that of fig8 . place 3 . 31 mg of the known crystal form i in a 5 ml vial , add 0 . 3 ml methanol and 3 ml sec - butyl alcohol ( the amount of the known crystal form i is 0 . 5 times of its solubility in the mixed solvent at room temperature ), sonicate for 5 min to get a clear solution , then filter it with 0 . 45 μm organic filter membrane , place the filtrate in an uncovered 5 ml vial and evaporate to recrystallize under nitrogen blowing , after 10 min , separate the solids by centrifugation , without drying , get crystal form iii described the present invention . the product is 2 . 05 mg and the yield is 62 %. the x - ray powder diffraction pattern is substantially consistent with that of fig8 . place 3 . 31 mg of the known crystal form i in a 5 ml vial , add 0 . 5 ml methanol and 1 ml n - butanol ( the amount of the known crystal form i is 0 . 8 times of its solubility in the mixed solvent at room temperature ), sonicate for 5 min to get a clear solution , then filter it with 0 . 45 μm organic filter membrane , place the filtrate in an uncovered 5 ml vial and evaporate to recrystallize under nitrogen blowing , after 10 min , separate the solids by centrifugation , without drying , get crystal form iii described by the present invention . the product is 3 . 00 mg and the yield is 91 %. the x - ray powder diffraction pattern is substantially consistent with that of fig8 . place 44 . 20 mg of the known crystal form i in a 20 ml vial , add 2 ml methanol and 5 ml tetrahydrofuran ( the amount of the known crystal form i is 1 time of its solubility in the mixed solvent at room temperature ), sonicate for 5 min to get a clear solution , then filter it with 0 . 45 μm organic filter membrane , place the filtrate in an uncovered 20 ml vial and evaporate to recrystallize at room temperature , separate the solids by centrifugation , vacuum drying for 16 hours at 40 ° c ., get crystal form iv of the present invention . the product is 43 . 0 mg and the yield is 97 %. the x - ray powder diffraction pattern is shown in fig1 . the dsc thermogram is shown in fig2 : the crystal form iv has a broad and large endothermic peak ( the solvent peak ) at 15 ° c .˜ 105 ° c ., the melting range of the dehydrated sample is 132 ° c .˜ 148 ° c ., followed by an exothermic form transformation peak at 200 ° c .˜ 245 ° c . and a melting point at 249 ° c . the tga thermogram is shown in fig3 : the weight loss of crystal form iv prior to 65 ° c . is about 4 . 3 % ( approximately 1 . 5 water molecules ), and the decomposition temperature is 291 ° c . the dynamic vapor sorption isothermal plot is shown in fig4 , showing a weight change of 2 . 0 % between 20 % rh - 80 % rh . the 1 hnmr is shown in fig5 , indicating a methanesulfonate salt . place 22 . 22 mg of the known crystal form i in a 20 ml vial , add 15 ml acetone ( the amount of the known crystal form i is 0 . 8 times of its solubility in acetone at room temperature ), sonicate for 5 min to get a clear solution , then filter it with 0 . 45 μm organic filter membrane , place the filtrate in an uncovered 20 ml vial and evaporate to recrystallize at room temperature , separate the solids by centrifugation , vacuum drying the solids for 16 hours at 40 ° c ., get crystal form iv described by the present invention . the product is 20 . 18 mg and the yield is 91 %. the x - ray powder diffraction pattern is substantially consistent with that of fig1 . place 9 . 58 of mg the known crystal form i in a 20 ml vial , add 15 ml isopropanol ( the amount of the known crystal form i is 0 . 5 times of its solubility in isopropanol at room temperature ), sonicate for 5 min to get a clear solution , then filter it with 0 . 45 μm organic filter membrane , place the filtrate in an uncovered 20 ml vial and add 0 . 35 mg of polyacrylic acid ( the molecular weight is about 5000 ), evaporate to recrystallize at room temperature , separate the solids by centrifugation , vacuum drying the solids for 16 hours at 40 ° c ., get crystal form iv described by the present invention . the product is 8 . 95 mg and the yield is 93 %. the x - ray powder diffraction pattern is substantially consistent with that of fig1 . place 5 . 02 mg of the crystal form ii in a 5 ml vial , vacuum drying the solids for 16 hours at 40 ° c ., and get crystal form iv described by the present invention . the product is 4 . 90 mg and the yield is 98 %. the x - ray powder diffraction pattern is substantially consistent with that of fig1 . take 4 . 20 mg of crystal form ii and run it in tga , using the following procedure : “ high - resolution sensitivity 3 . 00 , resolution 5 . 00 , heating to 120 ° c . at a rate of 10 . 00 ° c ./ min ”; after the procedure , let it cool naturally to room temperature ; then , place the sample in air for 1 h to obtain crystal form iv described by the present invention . the product is 4 . 05 mg and the yield is 96 %. the x - ray powder diffraction pattern is substantially consistent with that of fig1 . take 5 . 00 mg of the crystal form v ( prepared by example 13 ) and let it sit uncovered at room temperature for 30 min , and get crystal form iv described by the present invention . the product is 5 . 00 mg and the yield is 100 %. the x - ray powder diffraction pattern is substantially consistent with that of fig1 . place 8 . 52 mg of the crystal form iv in a copper pan preheated to 60 ° c ., kept it at 60 ° c . for 1 hour , and get crystal form v described by the present invention . the product is 8 . 07 mg and the yield is 95 %. the x - ray powder diffraction pattern is as shown in fig9 . components in each capsule : 71 mg active pharmaceutical ingredient ( api , selected from the group consisting of the crystal forms of dabrafenib methanesulfonate of the present invention , including crystal form ii , crystal form iii , crystal form iv and crystal form v )+ 60 mg microcrystalline cellulose ( avicel )+ 13 mg sodium carboxymethyl starch ( ssg ). each size 0 # hard capsule contains 144 mg of powders . the weight of avicel / ssg may be reasonably approximate . 1 ) appropriately / according to the actual need , separate thard capsules into halves and mark / identify each half . 2 ) place the bottom halves of the capsules in capsule filling machine , with the filling funnel on the top . 3 ) weigh each component ( avicel , ssg , api ) on thin weighing paper ( between each weighing , be sure to coat tar on the analytical balance ). 5 ) carefully and thoroughly mix the dry powders on the thin weighing paper with a small spatula . 7 ) place the top halves of the capsules on the capsules , close tightly , then shake the capsules to blend / disperse the components . 8 ) if the powders are filled near the top of the capsules , slightly tap the capsule by hand to settle down the powders . 9 ) place such capsules in a small appropriately marked bottle ( which should be large enough to remove the capsules easily ). “ qs ” in the above table means that such solvent or water will be removed in the final product . 1 ) sieve lactose monohydrate , colloidal silicon dioxide , cross - linked polyvinylpyrrolidone and half polyvinylpyrrolidone . 2 ) add api ( selected from the crystal forms of dabrafenib methanesulfonate of the present invention , including crystal form ii , crystal form iii , crystal form iv and crystal form v ). 3 ) granulate the mixture in a high - shear granulator with granulating solution containing dissolved polysorbate 80 and other half polyvinylpyrrolidone in purified water . 4 ) using comil 197 with a 0 . 375 ″ screen to grind the granules . 6 ) using comil 197 with a 0 . 075 ″ screen to grind the granules . compare the stability , the hygroscopicity , melting points , decomposition temperatures and dissolution profiles of crystal form iv prepared by example 7 and the known crystal form i . the results are shown in table 1 . the stability is performed by comparing the storage stability and the stirring test in water on crystalline forms . the storage stability is performed by placing the samples under a constant condition ( i . e . under constant humidity or constant temperature ) for a certain period of time , and then comparing their xrpds before and after placement . the stirring test in water is performed by , for each crystalline form , adding an equal amount of the sample ( 10 mg ) to an equal amount of water ( 1 ml ) to form a suspension , stirring the suspensions for a certain time at room temperature , and then comparing their xrpds . fig1 is the xrpd comparison patterns of the known crystal form i at every stage in experimental example 1 , wherein , the samples from top to bottom are : dabrafenib free base hydrate , the sample obtained from stirring the known crystal form i in water for 15 min ( this xrpd pattern shows this sample &# 39 ; s crystalline form is consistent with the above - mentioned dabrafenib free base hydrate ), and the known crystal form i . fig1 is the xrpd comparison patterns of crystal form iv of the present invention at every stage in experimental example 1 , wherein , the samples from top to bottom are : the crystal form iv , the sample obtained from stirring the crystal form iv in water for 15 min ( this xrpd pattern shows this sample &# 39 ; s crystalline form is consistent with the above - mentioned crystal form iv , indicating it remains crystal form iv ), the sample obtained from stirring the crystal form iv in water overnight , and dabrafenib free base hydrate . compare hygroscopicity in weight changes of samples between 20 %- 80 % rh obtained by dvs tests . the comparison of dissolution profiles is performed by the following procedures : place about 6 mg the sample in a 20 mg vial , add 15 ml ultrapure water , and then seal the vial . a suspension is obtained from sonication with a working power of 40 khz at room temperature , then take 1 ml of the suspension at 10 min , 30 min , 2 hr and 6 hr , respectively ; filter it with 0 . 45 μm organic filter membrane to , take the filtrate to be measured by hplc ; stir the remaining suspension for 16 hr at room temperature , and then filter it with 0 . 45 μm organic filter membrane , take the filtrate to be measured by hplc . fig1 is the comparison plot of dissolution profiles of crystal form iv and the known crystal form i in 1 ) when stored for one month at room temperature or at room temperature − 97 % rh , respectively , crystal form iv and the known crystal form i remained unchanged . 2 ) the known crystal form i converted to its free base after stirred for 15 minutes in the water suspension ( converted to the free base monohydrate confirmed by tga and its xrpd is consistent with that of the patent application pct / cn2014 / 074883 ); while crystal form iv still remained as methanesulfonate after stirred for 15 minutes in the water suspension ( the 1 hnmr spectrum is consistent with fig5 ; its xrpd pattern is consistent with that of the above - mentioned crystal form iv , indicating it remained crystal form iv ); crystal form iv converted to its free base after stirred overnight ( confirmed by tga as the free base monohydrate and its xrpd is consistent with that of the patent application pct / cn2014 / 074883 ). these indicate that crystal form iv is better in maintaining in the state of methanesulfonate that has higher than that of free base , and crystal form iv has better stability in water or aqueous system . 3 ) comparing the dissolution profiles from 0 ˜ 22 h , the dissolution rate of crystal form iv is higher than that of the known crystal form i at any test point . this indicates that crystal form iv has better dissolution rate and bioavailabilty . the stability of the known crystal form i of dabrafenib methanesulfonate and crystal form iv of the present invention during wet granulation in formulation process was studied . wet granulation experiments in the formulation process were parallel experiments . the specific steps are : 1 ) blend api ( the known crystal form i or crystal form iv of the present invention ), lactose ( monohydrate ) and microcrystalline cellulose uniformly . 2 ) make the above mixture into soft materials by using appropriate amount of 50 % aqueous ethanol solution , screen to produce wet granules . 3 ) dry the wet granules and then granulate them , blend with polyethylene glycol 6000 uniformly and then compress them into tablets . characterize the known crystal form i and crystal form iv of the present invention samples obtained from the formulation process of : ( 1 ) the sample obtained from physically mixing lactose monohydrate and microcrystalline cellulose at the ratios per the formulation ; ( 2 ) the sample obtained from physically mixing of api , lactose monohydrate and microcrystalline cellulose at the ratios per the formulation ; ( 3 ) the wet granule sample obtained from the wet granulation process ( excluding the compressed tablets in step 3 ). see xrpds in fig1 and fig1 . 1 ) with respect to the known crystal form i , compared with the xrpd of the sample ( 2 ) obtained from physically mixing api , lactose monohydrate and microcrystalline cellulose at ratios per the formulation , the xrpd of the wet granule sample ( 3 ) obtained from the wet granulation process ( excluding the compressed tablets in step 3 ) shows that the api has partially or totally converted to dabrafenib free base hydrate ( confirmed by tga as free base monohydrate and its xrpd is consistent with that of the patent application pct / cn2014 / 074883 ). these indicate that the known crystal form i is unstable in the wet granulation process . 2 ) with respect to crystal form iv , compared with the xrpd of the sample ( 2 ) obtained from physically mixing api , lactose monohydrate and microcrystalline cellulose at ratios per the formulation , the xrpd of the wet granule sample ( 3 ) obtained from the wet granulation process ( excluding the compressed tablets in step 3 ) shows that the api still kept as dabrafenib methanesulfonate ( the 1 hnmr spectrum is consistent with fig5 ; the xrpd pattern shows that it is consistent with that of the above - mentioned crystal form iv , indicating that it remained as crystal form iv ). these indicate that crystal form iv is stable in the wet granulation process . the above experiments show that , crystal form iv of the present invention is more stable in the wet granulation process and is easier to granulate ; therefore , it is an advantageous crystal form . in addition , after the tablets of crystal form iv were stored for 1 month at 25 ° c ./ 60 % rh , its crystal form still is stable . compare the capsule dissolution rate of crystal form iv prepared by example 7 with that of the known crystal form i . the capsule formulation is : the dissolution rate was performed by reference of chinese pharmacopoeia 2010 , using the paddle method . use 500 ml 0 . 1 % lauryl sodium sulfate aqueous solution as the dissolution medium , keep the temperature at 37 ° c . and the stirring speed at 50 rpm ; withdraw a 3 ml specimen at each of the times : 2 min , 5 min , 10 min , 30 min , 60 min and 120 min ; replace the aliquots withdrawn for analysis with equal volumes of 0 . 1 % lauryl sodium sulfate aqueous solution . perform hplc analysis on samples from each time interval for concentration information . see results in table 2 . from the results in table 2 , it is concluded that comparing the dissolution quantity of 0 ˜ 120 min , the dissolution quantity of crystal form iv capsule is larger than that of the known crystal form i capsule at any test point . this indicates that crystal form iv capsule has better dissolution rate and bioavailabilty . all patent documents and non - patent publications referred to herein are incorporated by reference entirely into the present application . in the present application , the above general description of the invention and the description of specific embodiments shall not be considered as the restriction on the technical scheme of such invention . the technicians in this field , according to the disclosure of the present application and under the precondition of not violating the elements constituting the related invention , may add , reduce or combine the technical features disclosed in the above general description or / and specific embodiments , so as to form other technical schemes within the present invention .